Products for Research Use Only

Fenbendazole-d3

CAT: 0804-HY-B0413S-01Size: 1 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-B0413S-01Size:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Fenbendazole-d3 is a deuterium labeled Fenbendazole. Fenbendazole-d3 is a HIF-1α agonist and activates the HIF-1α-related GLUT1 pathway. Fenbendazole is an orally active benzimidazole anthelmintic agent, with a broad antiparasitic range. Fenbendazole is a microtubule destabilizing agent. Fenbendazole causes cell-cycle arrest and mitotic cell death, and has antitumor activity in mice xenografted with wild-type p53[1][2][3][4].
CAS Number
1228182-47-5
UNSPSC
12352005
Hazard Statement
H361, H373, H410
Target
Antibiotic; HIF/HIF Prolyl-Hydroxylase; Microtubule/Tubulin; Parasite
Type
Isotope-Labeled Compounds
Related Pathways
Anti-infection; Cell Cycle/DNA Damage; Cytoskeleton; Metabolic Enzyme/Protease
Applications
Metabolism-sugar/lipid metabolism
Field of Research
Infection
Purity
99.70
Solubility
DMSO : 5mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
O=C(OC([2H])([2H])[2H])NC1=NC2=CC=C(SC3=CC=CC=C3)C=C2N1
Molecular Formula
C15H10D3N3O2S
Molecular Weight
302.37
Precautions
H361, H373, H410
References & Citations
[1]Nilambra Dogra, et al. Fenbendazole acts as a moderate microtubule destabilizing agent and causes cancer cell death by modulating multiple cellular pathways. Sci Rep. 2018 Aug 9;8 (1) :11926.|[2]Hossein Aleyasin, et al. Antihelminthic benzimidazoles are novel HIF activators that prevent oxidative neuronal death via binding to tubulin. Antioxid Redox Signal. 2015 Jan 10;22 (2) :121-34.|[3]Qiwen Duan, et al. Fenbendazole as a potential anticancer drug. Anticancer Res. 2013 Feb;33 (2) :355-62.|[4]Jia Xu, et al. miR-143-5p suppresses breast cancer progression by targeting the HIF-1α-related GLUT1 pathway. Oncol Lett. 2022 May;23 (5) :147.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, protect from light)
Scientific Category
Isotope-Labeled Compounds
Clinical Information
No Development Reported